Suppr超能文献

人克隆褪黑素MT1和MT2受体的新型选择性配体。

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

作者信息

Audinot Valérie, Mailliet François, Lahaye-Brasseur Chantal, Bonnaud Anne, Le Gall Aude, Amossé Christophe, Dromaint Sandra, Rodriguez Marianne, Nagel Nadine, Galizzi Jean-Pierre, Malpaux Benoît, Guillaumet Gérald, Lesieur Daniel, Lefoulon François, Renard Pierre, Delagrange Philippe, Boutin Jean A

机构信息

Division de Pharmacologie Moléculaire et Cellulaire, Institut de Recherches Servier, 125, Chemin de Ronde, 78290 Croissy-sur-Seine, France.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. doi: 10.1007/s00210-003-0751-2. Epub 2003 May 23.

Abstract

Melatonin has a key role in the circadian rhythm relay to periphery organs. Melatonin exerts its multiple roles mainly through two seven transmembrane domain, G-coupled receptors, namely MT1 or MT2 receptors. A pharmacological characterization of these human cloned melatonin hMT1 and hMT2 receptors stably expressed in HEK-293 or CHO cells is presented using a 2-[125I]-iodo-melatonin binding assay and a [35S]-GTPgammaS functional assay. Both reference compounds and new chemically diverse ligands were evaluated. Binding affinities at each receptor were found to be comparable on either HEK-293 or CHO cell membranes. Novel non-selective or selective hMT1 and hMT2 ligands are described. The [35S]-GTPgammaS functional assay was used to define the functional activity of these compounds which included partial, full agonist and/or antagonist activity. None of the compounds acted as an inverse agonist. We report new types of selective antagonists, such as S 25567 and S 26131 for MT1 and S 24601 for MT2. These studies brought other new molecular tools such as the selective MT1 agonist, S 24268, as well as the non-selective antagonist, S 22153. Finally, we also discovered S 25150, the most potent melatonin receptor agonist, so far reported in the literature.

摘要

褪黑素在昼夜节律向周围器官的传递中起关键作用。褪黑素主要通过两种七跨膜结构域的G蛋白偶联受体,即MT1或MT2受体发挥其多种作用。本文采用2-[125I]-碘褪黑素结合试验和[35S]-GTPγS功能试验,对稳定表达于HEK-293或CHO细胞中的人克隆褪黑素hMT1和hMT2受体进行了药理学特性研究。对参考化合物和新的化学结构多样的配体均进行了评估。发现每种受体在HEK-293或CHO细胞膜上的结合亲和力相当。描述了新型非选择性或选择性的hMT1和hMT2配体。[35S]-GTPγS功能试验用于确定这些化合物的功能活性,包括部分、完全激动剂和/或拮抗剂活性。没有一种化合物表现为反向激动剂。我们报告了新型选择性拮抗剂,如MT1的S 25567和S 26131以及MT2的S 24601。这些研究带来了其他新的分子工具,如选择性MT1激动剂S 24268以及非选择性拮抗剂S 22153。最后,我们还发现了S 25150,它是迄今为止文献报道中最有效的褪黑素受体激动剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验